Evaluating the in vivo Efficacy of CD4i Antibody, m9

评估 CD4i 抗体 m9 的体内功效

• 批准号: 8103377
• 负责人: Antony S. Dimitrov
• 金额: $ 62.57万
• 依托单位: PROFECTUS BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-08 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8103377
• 关键词: Albumins; Animals; Antibodies; Antibody Formation; Antiviral Agents; Binding; Biological Assay; CCR5 gene; CXCR4 gene; Cell Line; Cell Size; Cells; Chinese Hamster Ovary Cell; Control Groups; Development; Dose; Drops; Drug Kinetics; Employment; Engineering; Epitopes; Exposure to; Fc Receptor; Glycoproteins; Goals; HIV; HIV Envelope Protein gp120; HIV vaccine; HIV-1; Human; IgG1; Immune response; Immunoglobulin Fragments; Immunoglobulin G; In Vitro; Infection; Infection Control; Intramuscular Injections; Macaca; Macaca mulatta; Mediating; Modification; Monkeys; Outsourcing; Production; Property; Prophylactic treatment; Proteins; Role; Solutions; Spottings; Testing; Vaccines; Variant; Viral; Viral Load result; Virus; base; chemokine receptor; hydroxy-aluminum polymer; improved; in vivo; interest; neutralizing antibody; protective efficacy; protein aminoacid sequence; protein structure; public health relevance; receptor binding; rectal; response; success; therapeutic target; transmission process; vaccine development